P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier

Drug Metabolism and Disposition

Volumn 36, Issue 2, 2008, Pages 427-434

  Ose, Atsushi ^a   Kusuhara, Hiroyuki ^a   Yamatsugu, Kenzo ^a   Kanai, Motomu ^a   Shibasaki, Masakatsu ^a   Fujita, Takuya ^b   Yamamoto, Akira ^c   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b RITSUMEIKAN UNIVERSITY   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; BREAST CANCER RESISTANCE PROTEIN; CARBOXYLESTERASE; ELACRIDAR; ESTERASE INHIBITOR; GLYCOPROTEIN P; MESSENGER RNA; OSELTAMIVIR; VALSPODAR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MALE; MOUSE; MULTIDRUG RESISTANCE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; WILD TYPE;

ACETAMIDES; ACRIDINES; ANIMALS; ANTIVIRAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE; DOGS; LLC-PK1 CELLS; MALE; MICE; MICE, KNOCKOUT; OSELTAMIVIR; P-GLYCOPROTEINS; PRODRUGS; RATS; RATS, WISTAR; RNA, MESSENGER; SWINE; TETRAHYDROISOQUINOLINES;

MUS; RATTUS;

EID: 38749108824     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.018556     Document Type: Article

References (37)

1. Allen JD, Brinkhuis RF, Wijnholds J, and Schinkel AH (1999) The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59:4237-4241.
2. Bardsley-Elliot A and Noble S (1999) Oseltamivir. Drugs 58:851-860; discussion 861-852.
3. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582.
4. Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Muller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, et al. (2005) Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther 78:182-190.
5. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, and Lee EJ (2003) Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13:89-95.
6. Enokizono J, Kusuhara H, and Sugiyama Y (2007) Role of breast cancer resistance protein (Bcrp/Abcg2) in the disposition of phytoestrogens: the importance of Bcrp in the efflux transport in the blood-brain and -testis barriers. Mol Pharmacol 72:967-975.
7. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, and Borst P (2000) Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 83:366-374.
8. Fromm MF (2002) The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 54:1295-1310.
9. Fuyuno I (2007) Tamiflu side effects come under scrutiny. Nature 446:358-359.
10. Goralski KB, Acott PD, Fraser AD, Worth D, and Sinal CJ (2006) Brain cyclosporin A levels are determined by ontogenic regulation of mdr1a expression. Drug Metab Dispos 34:288-295.
11. Hasegawa T, Sugeno N, Takeda A, Matsuzaki-Kobayashi M, Kikuchi A, Furukawa K, Miyagi T, and Itoyama Y (2007) Role of Neu4L sialidase and its substrate ganglioside GD3 in neuronal apoptosis induced by catechol metabolites. FEBS Lett 581:406-412.
12. He G, Massarella J, and Ward P (1999) Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 37:471-484.
13. Hill G, Cihlar T, Oo C, Ho ES, Prior K, Wiltshire H, Barrett J, Liu B, and Ward P (2002) The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos 30:13-19.
14. Izumi T, Hosiyama K, Enomoto S, Sasahara K, and Sugiyama Y (1997) Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data. J Pharmacol Exp Ther 280:1392-1400.
15. Izumi Y, Tokuda K, O'Dell KA, Zorumski CF, and Narahashi T (2007) Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett 426:54-58.
16. Kikuchi R, Kusuhara H, Abe T, Endou H, and Sugiyama Y (2004) Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors across the blood-brain barrier. J Pharmacol Exp Ther 311:1147-1153.
17. Kikuchi R, Kusuhara H, Sugiyama D, and Sugiyama Y (2003) Contribution of organic anion transporter 3 (Slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier. J Pharmacol Exp Ther 306:51-58.
18. Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, et al. (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119:681-690.
19. Kim RB (2002) MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 12:425-427.
20. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, and Gottesman MM (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528.
21. Kusuhara H and Sugiyama Y (2001) Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part 1). Drug Discov Today 6:150-156.
22. Lindegardh N, Davies GR, Tran TH, Farrar J, Singhasivanon P, Day NP, and White NJ (2006) Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrob Agents Chemother 50:3197-3199.
23. Maines LW, Antonetti DA, Wolpert EB, and Smith CD (2005) Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 49:610-617.
24. Matsuoka Y, Okazaki M, Kitamura Y, and Taniguchi T (1999) Developmental expression of P-glycoprotein (multidrug resistance gene product) in the rat brain. J Neurobiol 39:383-392.
25. Rousselle CH, Lefauconnier JM, and Allen DD (1998) Evaluation of anesthetic effects on parameters for the in situ rat brain perfusion technique. Neurosci Lett 257:139-142.
26. Sadeque AJ, Wandel C, He H, Shah S, and Wood AJ (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231-237.
27. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, and Unadkat JD (2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77:503-514.
28. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, and La Du BN (2002) Current progress on esterases: from molecular structure to function. Drug Metab Dispos 30:488-493.
29. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
30. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, and Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
31. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, and Yan B (2006) Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319:1477-1484.
32. Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee YJ, Maeda J, Ikoma Y, Ito H, Suzuki K, et al. (2006) Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J Nucl Med 47:1427-1433.
33. Takasato Y, Rapoport SI, and Smith QR (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247:H484-H493.
34. Tamai I and Tsuji A (2000) Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 89:1371-1388.
35. Wiltshire H, Wiltshire B, Citron A, Clarke T, Serpe C, Gray D, and Herron W (2000) Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B Biomed Sci Appl 745:373-388.
36. Yamaguchi K, Hata K, Koseki K, Shiozaki K, Akita H, Wada T, Moriya S, and Miyagi T (2005) Evidence for mitochondrial localization of a novel human sialidase (NEU4). Biochem J 390:85-93.
37. Yamatsugu K, Kamijo S, Suto Y, Kanai M, and Shibasaki M (2007) A concise synthesis of Tamiflu: third generation route via the Diels-Alder reaction and the Curtius rearrangement. Tetrahedron Lett 48:1403-1406.